NCT05210348 (Urine-hrHPV) is a clinical trial in Human Papillomavirus Infection, sponsored by Peking University People's Hospital.

Who is sponsoring NCT05210348?

NCT05210348 is sponsored by Peking University People's Hospital.

What condition does NCT05210348 study?

NCT05210348 studies Human Papillomavirus Infection, Cervical Cancer, Human Papilloma Virus, Negative for Intraepithelial Lesion or Malignancy, Atypical Squamous Cells of Undetermined Significance, Cervical Squamous Intraepithelial Lesion, Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion, High-Grade Squamous Intraepithelial Lesions, Cervical Intraepithelial Neoplasia Grade I, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III, Atypical Glandular Cells, Atypical Glandular Cells Not Otherwise Specified, Atypical Glandular Cells, Favor Neoplastic, Cervical Squamous Cell Carcinoma, Adenocarcinoma in Situ, Cervical Adenocarcinoma.

Is NCT05210348 still recruiting?

NCT05210348 is currently status unknown. Last updated 27 January 2022.

Last reviewed 2022-01-27 · How we verify

NCT05210348: Urine-hrHPV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of Detection of High Risk HPV in Urine

Status unknown Last updated 27 January 2022

What this trial tests

trial in Human Papillomavirus Infection in 1,000 participants. Status unknown.

Timeline

15 September 2021

Primary endpoint
1 February 2022

1 May 2022

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	15 September 2021
Primary completion	1 February 2022
Estimated completion	1 May 2022
Sites	3 locations across China

Conditions studied

Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
Cervical Cancer — all drugs for Cervical Cancer →
Human Papilloma Virus — all drugs for Human Papilloma Virus →
Negative for Intraepithelial Lesion or Malignancy — all drugs for Negative for Intraepithelial Lesion or Malignancy →

Sponsor

Peking University People's Hospital

Who can join

Adults 20 to 65, female only, with Human Papillomavirus Infection or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Performance of a Dedicated Urine-Based Assay for the Detection of Human Papillomavirus and Cervical Intraepithelial Neoplasia.
Zhao Y, Zhao L, Wang Z, Cui S, et al · · 2023 · cited 3× · PMID 38077232 · DOI 10.2147/ijwh.s424621

Verify or expand the search:

Other recruiting trials for Human Papillomavirus Infection

Currently open trials in the same condition.

NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05210348 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 27 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing